Halozyme Therapeutics, Inc.

HALO · Health care (biological products, (no diagnostic substances)) · 10 years of annual accounts filed with the SEC · latest fiscal year ended 2025-12-31

Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›

Halozyme Therapeutics, Inc. reported revenue of $1.4 billion in fiscal 2025, after growing 28.5% a year over the previous 9 years. Its operating margin widened from -56.7% in 2016 to 33.6%, and it earned 14.5% on its invested capital in the latest year. Of the $2.1 billion its operations generated over 10 years, 91.9% went to buybacks and 83.6% to acquisitions; the share count fell 3.2%. On the accounting screens, it passes 5 of 9 Piotroski tests, its Altman Z'' of 3.02 is in the safe zone and its Beneish M-score is below the -1.78 line; 2 of the six cross-checks between its statements fire.

Revenue, fiscal 2025 1.4B +28.5% a year over 9 years

Operating margin 33.6% gross margin 83.6%

Return on invested capital 14.5% 15.6% on average over 5 years

Free cash flow after stock pay 593.0M 42.5% of revenue

Net debt ÷ EBITDA 4.2× net debt 2.0B

Piotroski F-score 5/9 tests of improvement passed

Is it growing?

Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.

RevenueOperating income

Compound growth a year
	3 yrs	5 yrs	9 yrs
Revenue	+28.4%	+39.2%	+28.5%
Operating income	+20.6%	+26.6%	—
Net income	+16.2%	+19.7%	—
Earnings per share	+21.2%	+22.9%	—
Free cash flow per share	+45.9%	+69.3%	—
Shares	-4.1%	-2.6%	-0.4%

Falling shares are buybacks: each remaining share owns more of the company.

Does it earn more than its capital costs?

Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.

    GrossOperatingNetFree cash flow
    
  

Return on invested capital

Return on invested capital Cost of capital today · 3.7%

Economic profit

(return on capital − cost of capital) × capital invested: the profit left after paying for the money used. Today's cost of capital is applied to every year, since a past one cannot be rebuilt honestly.

Return on equity: 649.2%
Return on assets: 12.5%
Asset turnover: 0.55×
Research & development: 5.8% of revenue
Overheads (SG&A): 14.8% of revenue

Is the profit cash, and where does the cash go?

Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.

Net incomeFree cash flowAfter stock-based pay

Where 10 years of operating cash went, 2016–2025

2.1B generated by the business. Each band is its share of that total.

Reinvested in the business 3% 54.9M
Acquisitions 84% 1.7B
Dividends 0% 0
Share buybacks 92% 1.9B
More than it generated: funded with cash or new debt -78% -1.6B

Over the same years it paid 320.7M in stock. The share count fell 3.2%. 1.6B of the buybacks went beyond offsetting that dilution.

Per share

    Earnings per shareFree cash flow per shareDividend per share
    
  

Shares outstanding

Diluted shares

Debt and liquidity

Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.

Net debt

Net debt ÷ EBITDA: 4.2×
Interest coverage: 26× operating income ÷ interest
Current ratio: 4.66 current assets ÷ current liabilities
Cash conversion cycle: 360 days collects in 111d, stock 282d, pays in 33d

Three classic screens of the accounts

Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.

Piotroski F-score

Is the business improving? Nine yes-or-no tests, this year against last.

5of 9 tests passed

ProfitableReturn on assets above zero passed
Cash from operationsOperating cash flow above zero passed
Profitability improvedReturn on assets higher than a year before failed
Profit backed by cashOperating cash flow above net income (low accruals) passed
Less long-term debtLong-term debt as a share of assets fell failed
More liquidCurrent ratio higher than a year before failed
No new sharesShare count did not grow passed
Better gross marginGross margin higher than a year before failed
Sells more per assetAsset turnover higher than a year before passed

Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.

Altman Z''-score

Does the balance sheet look like those of companies that went bankrupt?

3.02safe zone

Working capital ÷ assets 0.26 × 6.56+1.68
Retained earnings ÷ assets 0.02 × 3.26+0.07
Operating income ÷ assets 0.19 × 6.72+1.25
Equity ÷ liabilities 0.02 × 1.05+0.02

Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.

Beneish M-score

Do the accounts resemble those of companies that manipulated their earnings?

-2.56below the -1.78 line

Receivables vs sales 1.08+0.99
Gross margin slipping 1.01+0.53
Soft assets 1.44+0.58
Sales growth 1.38+1.23
Slower depreciation 0.98+0.11
Overheads vs sales 0.98-0.17
Profit not in cash -0.13-0.62
Leverage rising 1.15-0.38

Where it misleads: fast growth and acquisitions. Sales growth carries a heavy weight, so a company growing 50% a year scores like a suspect without having done anything. It is a screen from a 1999 study, not an accusation.

Where the statements disagree

Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.

Capital spending (7M) is well below depreciation (11M).

Benign

Mature assets, or a business that has become less capital-intensive.

Worrying

Under-investing: today's profit is being held up by consuming tomorrow's capacity.

Net debt is 4.2 times EBITDA.

Benign

A stable sector with predictable cash flows and comfortable maturities.

Worrying

Little room if earnings fall; the maturity schedule is what to check.

What is it worth, under which assumptions?

A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.

Revenue

Starting revenue

M $

revenue of fiscal 2025

Growth in year one

revenue grew +39.2% a year over the last 5 years; it fades to the terminal rate by the last year

Years until it settles

yrs

ten years for growth to fade to the terminal rate

Cash from each sale

Free cash flow margin today

free cash flow to the firm after stock-based pay ÷ revenue, last 3 fiscal years together

Margin in the last year

the margin in year ten; by default the business keeps today's

Count stock-based pay as a costIt is paid in shares instead of cash, and shareholders bear it through dilution. Most free cash flow figures leave it out.

The long run

Growth after that, forever

growth forever after year ten, below the risk-free rate: no company outgrows the economy forever

The discount rate

Risk-free rate

10-year US Treasury par yield (U.S. Treasury), 2026-09-28

Beta

not measured on this public page, which uses only public filings: 1.0 assumes it moves like the market. Sign in to measure it from prices

Equity risk premium

the extra return demanded for holding shares; it cannot be measured, and 4–6% is the common range

Cost of debt, before tax

interest expense ÷ debt = 0.8%, kept between the risk-free rate and +8 points

Tax rate

effective rate in the last fiscal year, 32.1%, kept within 0–35%

The price

Share price

Type the price you see at your broker. It is used only for the reverse questions: what that price implies.

Back to the defaults

SEC from the filings Treasury the 10-year yield measured from prices assumption cannot be measured yours you changed it

91% of the value comes from after year 10: this valuation rests mostly on the long run, which is exactly what is least known.

Value per share, with these assumptions $489.01 discounted at 3.7% a year · 91% of it from after year 10

$177.4780% of 2,994 simulations$532.78

Cautious $146.84 21.0% growth · 16.5% margin · 4.7% discount · 2.0% forever

Your assumptions $489.01 25.0% growth · 19.5% margin · 3.7% discount · 2.5% forever

Generous — 29.0% growth · 22.4% margin · 2.7% discount · 3.0% forever

Type a share price on the left to ask the reverse questions: what growth, what margin or what discount rate that price implies.

What the value implies, in the usual multiples

	At this model's value
Price ÷ earnings	191.2×
Enterprise value ÷ EBITDA	130.3×
Enterprise value ÷ revenue	44.8×
Free cash flow yield	1.0%

From cash flows to a value per share

10 years of cash flow, today5.5B

Everything after, today57.1B

The whole business62.6B

Minus net debt-2.0B

What belongs to shareholders60.6B

Divided among 123.9M shares: $489.01 each.

The projection next to its history

Reported free cash flow after stock pay, then the model's. A projection that looks nothing like the past needs a reason.

ReportedProjected

Year by year

	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Revenue	1.7B	2.1B	2.6B	3.0B	3.5B	3.9B	4.3B	4.6B	4.8B	5.0B
Growth	25.0%	22.5%	20.0%	17.5%	15.0%	12.5%	10.0%	7.5%	5.0%	2.5%
Cash margin	19.5%	19.5%	19.5%	19.5%	19.5%	19.5%	19.5%	19.5%	19.5%	19.5%
Free cash flow	339.7M	416.1M	499.3M	586.7M	674.7M	759.1M	835.0M	897.6M	942.5M	966.1M
Worth today	327.6M	386.9M	447.7M	507.3M	562.5M	610.2M	647.3M	670.9M	679.3M	671.4M

If the least-known inputs move

Value per share as two inputs change at a time. Neighbouring cells that differ a lot are the conclusion: the value depends on numbers nobody knows to a point.

The discount rate and growth forever

discount ↓ · forever →	1.5%	2.0%	2.5%	3.0%	3.5%
2.7%	508	868	2,944	—	—
3.2%	351	497	850	2,883	—
3.7%	266	345	489	838	2,886
4.2%	211	259	336	477	816
4.7%	174	206	254	329	467

Year-one growth and the final margin

margin ↓ · growth →	21.0%	23.0%	25.0%	27.0%	29.0%
15.6%	329	359	392	427	464
17.5%	370	404	440	479	522
19.5%	411	449	489	533	579
21.4%	452	493	538	585	637
23.4%	493	538	587	639	695

All the inputs moving at once

2,994 valuations, each with growth, final margin, discount rate and growth forever drawn at random around the values on the left (spreads of 3.0%, 2.9%, 1.0% and 0.5%). Not a probability — the spreads are assumptions too — but an honest picture of how wide the answer is.

10th percentile$177.47

Median$320.51

90th percentile$532.78

Half of the simulations land between $234.91 and $432.63; one in ten below $177.47, one in ten above $532.78.

Does the long run make sense?

48.1×The terminal value prices the business in year 10 at 48.1 times that year's EBITDA.
17%To grow 2.5% forever while reinvesting 15% of its after-tax operating profit, the business must earn 17% on the new capital — it has earned 16% on average over the last five years.
91%of the value comes from after year 10. The more of it, the more the answer depends on the part nobody can see.

The discount rate, taken apart

What shareholders demand (CAPM): 5.24% risk-free + 1.00 beta × 5.0% premium = 10.24%.
What lenders charge, after the tax saving on interest: 5.24% × (1 − 32.1%) = 3.56%.
Weighted by how much of each the company uses (book value (no price given)): 3.71%, the rate every future cash flow is discounted at.

What it has filed lately

The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.

Event 2026-09-22

Signed a material agreement; took on a financial obligation; sold shares outside a registration

Event 2026-09-18

Published other information

Event 2026-09-16

Published other information

Event 2026-08-18

Changed a director or officer

Changed a director or officer

Results 2026-05-11

Reported results

Estimatein 38d

Results for the period ending 2026-09-29

What its own directors and officers did

Every Form 4 filed in the last twelve months, read line by line: 6 filings by 4 people. Open-market purchases and sales are counted apart from awards, option exercises and shares withheld for taxes.

Bought on the open market—none in the period

Sold on the open market$15.1M25 sale(s) by 3 insider(s)

Under pre-arranged plans100%of the sales followed a 10b5-1 plan set months earlier

Other lines81 awards · 7 option exercises · 0 tax withholdings

Date	Who	What	Shares	Price	Value	Holds after
16 Sep 2026	Posard Matthew L.Director	Sold on the open market · pre-arranged plan	3,000	$106.83	$320,484	71,735
16 Sep 2026	Posard Matthew L.Director	Sold on the open market · pre-arranged plan	3,100	$106.13	$329,009	74,735
16 Sep 2026	Posard Matthew L.Director	Sold on the open market · pre-arranged plan	8,896	$108.04	$961,124	62,839
16 Sep 2026	Posard Matthew L.Director	Sold on the open market · pre-arranged plan	4,000	$108.99	$435,964	58,839
11 Sep 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	4,508	$107.55	$484,826	767,780
11 Sep 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	15,492	$107.15	$1.7M	772,288
11 Sep 2026	Torley HelenPRESIDENT AND CEO	Exercised options	20,000	$18.41	$368,200	787,780
10 Sep 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	14,588	$107.01	$1.6M	773,192
10 Sep 2026	Torley HelenPRESIDENT AND CEO	Exercised options	20,000	$18.41	$368,200	787,780
10 Sep 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	5,412	$107.58	$582,228	767,780
9 Sep 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	13,304	$107.22	$1.4M	774,476
9 Sep 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	100	$108.67	$10,867	767,780
9 Sep 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	6,596	$107.82	$711,187	767,880
9 Sep 2026	Torley HelenPRESIDENT AND CEO	Exercised options	20,000	$18.41	$368,200	787,780
1 Sep 2026	Appelhans DannielleDirector	Received as an award	1,161	—	—	1,161
19 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	7,200	$106.36	$765,778	780,580
19 Aug 2026	Torley HelenPRESIDENT AND CEO	Exercised options	20,000	$18.41	$368,200	787,780
19 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	9,600	$107.22	$1.0M	770,980
19 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	3,200	$107.77	$344,848	767,780
18 Aug 2026	Torley HelenPRESIDENT AND CEO	Exercised options	20,000	$18.41	$368,200	787,780
18 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	5,703	$103.08	$587,882	782,077
18 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	4,897	$104.11	$509,827	777,180
18 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	9,400	$104.87	$985,816	767,780
17 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	7,500	$103.48	$776,115	767,780
17 Aug 2026	Torley HelenPRESIDENT AND CEO	Exercised options	20,000	$18.41	$368,200	787,780
17 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	900	$98.96	$89,062	786,880
17 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	500	$100.46	$50,228	786,380
17 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	2,100	$101.77	$213,709	784,280
17 Aug 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	9,000	$102.55	$922,977	775,280
10 Aug 2026	Connaughton BernadetteDirector	Sold on the open market · pre-arranged plan	1,626	$102.80	$167,153	40,418
8 Jul 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	888	$79.28	$70,397	768,815
8 Jul 2026	Torley HelenPRESIDENT AND CEO	Sold on the open market · pre-arranged plan	1,035	$80.19	$82,994	767,780
8 Jul 2026	Torley HelenPRESIDENT AND CEO	Exercised options	1,923	$12.07	$23,211	769,703

A Form 4 says what happened, when, how many shares and at what price. It does not say why: a sale can be diversification, a tax bill or a plan fixed months earlier, and an award is pay, not a purchase. Nothing here is a reason to buy or sell anything.

Which large funds report holding it

From the Form 13F of the 28 institutions followed on this site, as of the end of their last reported quarter. A 13F is filed up to 45 days later and shows only long positions in US-listed shares.

Fund	Shares	Value	Share of the fund	Since the quarter before
Norges Bank (Norway's sovereign fund) 30 Jun 2026	1.5M	$116.1M	0.0%	New
Bridgewater Associates 30 Jun 2026	463,146	$36.3M	0.1%	Reduced

All the funds and what they reported ›

Companies like this one

Same SEC industry (biological products, (no diagnostic substances)) first, then the rest of health care.

AMGN Amgen Inc GILD Gilead Sciences, Inc.MRNA Moderna, Inc.RVMD Revolution Medicines, Inc.BIIB Biogen Inc.NBIX Neurocrine Biosciences Inc EXEL Exelixis, Inc.TECH BIO-TECHNE Corp

Every figure, year by year

10 fiscal years · 30 measures

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Size
Revenue	146.7M	316.6M	151.9M	196.0M	267.6M	443.3M	660.1M	829.3M	1.0B	1.4B
Revenue growth	—	+115.8%	-52.0%	+29.1%	+36.5%	+65.7%	+48.9%	+25.6%	+22.4%	+37.6%
Operating income	-83.2M	81.0M	-69.3M	-67.6M	144.3M	275.9M	267.5M	337.6M	551.5M	469.0M
Net income	-103.0M	63.0M	-80.3M	-72.2M	129.1M	402.7M	202.1M	281.6M	444.1M	316.9M
Margins
Gross margin	77.4%	90.2%	93.3%	76.8%	83.8%	81.6%	78.9%	76.8%	84.3%	83.6%
Operating margin	-56.7%	25.6%	-45.7%	-34.5%	53.9%	62.2%	40.5%	40.7%	54.3%	33.6%
Net margin	-70.2%	19.9%	-52.9%	-36.9%	48.2%	90.8%	30.6%	34.0%	43.7%	22.7%
Free cash flow margin	-36.5%	41.9%	-35.7%	-45.6%	19.8%	67.2%	35.6%	45.0%	46.1%	46.2%
R&D ÷ revenue	102.8%	47.6%	98.9%	71.8%	12.8%	8.0%	10.1%	9.2%	7.8%	5.8%
SG&A ÷ revenue	31.3%	17.0%	40.0%	39.4%	17.1%	11.4%	21.7%	18.0%	15.2%	14.8%
Cash
Free cash flow	-53.5M	132.7M	-54.2M	-89.5M	53.0M	298.0M	235.3M	373.3M	468.4M	644.6M
Stock-based pay	25.6M	30.7M	35.7M	34.8M	17.2M	20.8M	24.4M	36.6M	43.4M	51.6M
Free cash flow after stock pay	-79.1M	102.0M	-89.9M	-124.2M	35.7M	277.2M	210.9M	336.7M	425.0M	593.0M
Free cash flow to the firm	-84.9M	87.4M	-101.3M	-101.4M	70.6M	119.5M	48.8M	233.2M	368.4M	160.7M
Free cash flow ÷ net income	0.5×	2.1×	0.7×	1.2×	0.4×	0.7×	1.2×	1.3×	1.1×	2.0×
Capex ÷ revenue	2.1%	0.4%	3.1%	2.1%	0.9%	0.3%	0.7%	1.8%	1.1%	0.5%
Returns
Return on invested capital	-45.7%	19.3%	-18.6%	-13.7%	26.3%	9.8%	13.0%	17.2%	23.5%	14.5%
Return on equity	—	30.2%	-32.3%	-78.7%	85.5%	204.5%	119.0%	336.0%	122.1%	649.2%
Return on assets	-39.4%	12.1%	-18.2%	-12.8%	22.3%	36.5%	11.0%	16.2%	21.5%	12.5%
Asset turnover	0.6×	0.6×	0.3×	0.3×	0.5×	0.4×	0.4×	0.5×	0.5×	0.6×
Economic profit	-91.0M	64.0M	-83.7M	-85.9M	123.7M	64.9M	155.1M	214.2M	370.3M	237.1M
Per share
Earnings per share	$-0.81	$0.45	$-0.56	$-0.50	$0.91	$2.74	$1.44	$2.10	$3.43	$2.56
Free cash flow per share	$-0.42	$0.95	$-0.38	$-0.62	$0.37	$2.03	$1.67	$2.78	$3.62	$5.20
Dividend per share	—	—	—	—	—	—	—	—	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—
Book value per share	$-0.25	$1.46	$1.72	$0.67	$1.12	$1.43	$1.26	$0.66	$2.95	$0.41
Diluted shares	128.0M	139.1M	143.6M	144.3M	141.5M	146.8M	140.6M	134.2M	129.4M	123.9M
Balance sheet
Net debt	149.9M	33.6M	68.4M	282.4M	249.5M	758.0M	1.3B	1.4B	1.4B	2.0B
Net debt ÷ EBITDA	-1.9×	0.4×	-1.0×	-4.4×	1.7×	2.7×	4.6×	4.0×	2.5×	4.2×
Interest coverage	-4.2×	3.7×	-3.8×	-5.8×	7.1×	36.7×	15.8×	18.0×	30.5×	25.9×
Current ratio	4.7×	3.9×	2.9×	6.3×	1.3×	7.9×	5.7×	6.6×	7.8×	4.7×
Cash conversion cycle (days)	160	-7	740	294	628	310	344	322	405	360
Scores
Piotroski F-score	—	7	3	3	7	4	4	7	9	5
Altman Z''	-4.49	3.26	0.52	1.23	0.88	6.54	3.50	3.93	5.60	3.02
Beneish M	—	-0.94	-1.74	-1.50	-1.09	-0.20	-0.44	-2.75	-2.38	-2.56

Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.